Amgen/Transkaryotic opening arguments

Attorneys for Amgen and for Transkaryotic Therapies and its partner Aventis presented opening arguments Monday morning in the U.S. District Court for the District of Massachusetts in a trial that will determine if TKTX can market its Gene Activated erythropoietin prior to the expiration of AMGN's EPO patents.

Because U.S. District Court Judge William Young has already ruled that TKTX's GA-EPO infringes patents covering AMGN's Epogen EPO, the arguments focused on the validity of Amgen's EPO patents (see BioCentury Extra, Wednesday April 26). ...